Jounce Therapeutics, JNCE is showing recent insider trading activity. Public SEC records indicate that Kevin Tang recently Bought $85,533 worth of shares on 2 months ago. With that said, our editors here at politicsandwallstreet.com, are adding JNCE to our watchlist to see if this momentum continues.
Based on this transaction and a few others from Corporate Insiders of JNCE that Sold $9.0K worth of shares in the last 3 months, the Insider Confidence level of Jounce Therapeutics is trending Down.
Since these insiders have unique insights into what's happening at Jounce Therapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for JNCE:
In addition, TradingView issued a Buy rating for JNCE over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook.
Here is a bit more on Jounce Therapeutics, JNCE but please do your own research.
JNCE Summary: Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to JNCE, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================
Based on this transaction and a few others from Corporate Insiders of JNCE that Sold $9.0K worth of shares in the last 3 months, the Insider Confidence level of Jounce Therapeutics is trending Down.
Since these insiders have unique insights into what's happening at Jounce Therapeutics, this might serve as an indicator of where it is headed.
Here is a list of the latest insider activity for JNCE:
- Kevin Tang - COO, Bought $85,533 worth of shares on 2 days ago
- Hugh Cole - >10% Owner, Sold $18,481 worth of shares on 2 months ago
- Drapkin Kimberlee C - CFO & Treasurer, Sold $15,661 worth of shares on 2 months ago
- Richard Ca Murray - CEO & President,Director, Sold $50,075 worth of shares on 2 months ago
In addition, TradingView issued a Buy rating for JNCE over the next month, Barchart.com has a sell rating and Yahoo! Finance has a Neutral short-term outlook.
Here is a bit more on Jounce Therapeutics, JNCE but please do your own research.
JNCE Summary: Jounce Therapeutics, Inc. is a clinical-stage immunotherapy company. It engaged in developing therapies which enable the immune system to attack tumors. The Company's lead product candidate, JTX-2011, is a clinical-stage monoclonal antibody that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of certain T cells found in a range of solid tumors. It also developing JTX-4014 for use in future combinations with JTX-2011, as well as for use in combination with other future product candidates. Jounce Therapeutics, Inc. is based in Cambridge, United States.
- Recent Last Price: $1.49
- Price Change: $0.43, 40.57%
- Yearly Gain: -84.61%
- Market Cap: $55.27M
- P/E Ratio: -1.075
One resource you need to consider using Tipranks.com where as a premium member you get access to all buy ratings, price targets and insider trading signals. Click here for more on Tipranks.com.
This information was sourced from various 3rd party public sources but to get the best insight into insider activity related to JNCE, you should consider joining TipRanks.com.
PoliticsAndWallStreet.com
Disclaimer: Sandpiper Marketing Group, LLC would like to remind you the data contained in this website is not necessarily real-time nor accurate. All stocks, indexes, futures and Forex prices are not provided by exchanges but rather by our editor research at the time of writing this release, and so prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Sandpiper Marketing does not bear any responsibility for any trading losses you might incur as a result of using this data. Sandpiper Marketing Group, LLC or anyone involved with Sandpiper Marketing Group, LLC will not accept any liability for loss or damage as a result of reliance on the information including data, quotes, charts and buy/sell signals contained within this website. Please be fully informed regarding the risks and costs associated with trading the financial markets, it is one of the riskiest investment forms possible. While all information is believed to be reliable, it is not guaranteed by us to be accurate. Individuals should assume that all information contained in this website/newsletter is not trustworthy unless verified by their own research. Also, because events/circumstances frequently do not occur as expected, there will likely be differences between any predictions and actual results. Always consult a real licensed investment professional before making any investment decision. Be extremely careful, investing in securities carries a high degree of risk; you may likely lose some or all of the investment.
==============================================================================